Highest-materiality recent filing
HOOKIPA shareholders approve asset sale to Gilead and company dissolution
Asset sale to Gilead Sciences approved: 5,063,462 for, 239,595 against, 1,502 abstain.
HOOKIPA plans voluntary delisting and deregistration ahead of asset sale to Gilead and dissolution
Intends to voluntarily delist from Nasdaq; Form 25 expected July 29, delisting effective ~August 8, 2025.
HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution
Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.
Record date for 2022 annual meeting was 78 days before the meeting (April 13 vs. June 30, 2022), violating DGCL 60-day limit.
Gilead, owning 19.4% of HOOKIPA shares, signals intent to vote for the deal and join the $30M+ fundraise.
HOOKIPA announces non-binding discussions to acquire Poolbeg Pharma in all-share deal
Poolbeg shareholders to receive 0.03 HOOKIPA shares per share; expected ~55% ownership of combined entity before planned $30M fundraise.
HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700
Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.
Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)
Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.
Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024
Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.
Dr. Malte Peters appointed CEO & President effective July 22, 2024; salary $630k, RSU award $700k.
HOOKIPA reports 53% ORR in CPS≥20 subgroup from Phase2 HB-200 + pembro trial at ASCO
Among 35 evaluable first-line HPV16+ HNSCC patients, ORR 37%, CR 11%, DCR 69% per RECIST 1.1.
HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024
Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.
HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination
Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.
Pivotal Phase 2/3 trial for HB-200 + pembrolizumab in first-line HPV16+ recurrent/metastatic OPSCC; FDA alignment achieved.
HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%
Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.
HOOKIPA Pharma transfers listing to Nasdaq Capital Market to regain bid price compliance
Received Nasdaq approval to transfer common stock listing from Global Select Market to Capital Market effective Feb 1, 2024.
HOOKIPA reports Roche termination of HB-700 deal, 30% workforce cut, $117.5M cash
Roche terminates collaboration for HB-700 (KRAS-mutated cancers) effective April 25, 2024; HOOKIPA regains full rights and remains eligible for IND milestone payment.
Gilead invests $21.25M in HOOKIPA for 15M shares at $1.4167 each
Gilead purchased 15M shares for ~$21.25M at $1.4167/share; now holds 19.4% of HOOK outstanding stock.
HOOKIPA reports Q3 2023 net loss of $19.1M; HB-200 shows 42% ORR in HPV16+ HNSCC
Revenue of $6.9M, up from $2.2M YoY, mainly from Gilead and Roche collaboration recognition.
HOOKIPA Q2 net loss $18M; HB-200 Phase 2 shows 43% ORR in HPV16+ head and neck cancer
Net loss $18.0M in Q2 2023 vs $16.4M in Q2 2022; revenue flat at $2.7M.
HOOKIPA Pharma receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Received Nasdaq letter on Aug 3, 2023 due to closing bid price below $1.00 for 30 consecutive business days.
HOOKIPA Pharma prices $50M public offering of common & convertible preferred stock
Priced 22,900,768 shares of common stock at $1.31/share and 15,268 Series A-2 convertible preferred shares at $1,310/share.
HB-200 + pembrolizumab showed 43% objective response rate (6/14 patients) in 1st-line HPV16+ head/neck cancer, doubling pembrolizumab alone.
Q1 net loss $19.7M vs $18.0M YoY; revenue $3.2M (up from $1.4M) on higher collaboration recognition.
HOOKIPA reports Q4 net loss $12.3M, cash $113.4M; HB-200 data expected 2Q2023
Cash $113.4M at Dec 31, 2022, plus $15M milestones from Roche & Gilead in early 2023; no SVB exposure.
Hookipa Q3 net loss $18.3M; cash $100.7M; secured Roche deal for KRAS-mutated cancers
Net loss $18.3M in Q3 2022 vs $20.0M in Q3 2021; revenue $2.2M (down from $3.9M).
HOOKIPA receives $25 million upfront; eligible for up to ~$930 million in total milestone payments plus tiered royalties.
HOOKIPA Q2 2022 revenue $2.7M, net loss $16.4M; FDA accepts IND for HB-300, HB-200 Phase 2 underway
Revenue $2.7M, down from $5.4M YoY due to lower cost reimbursements from Gilead collaboration.
HOOKIPA Phase 1 HB-200 shows 80% disease control with alternating 2-vector; Phase 2 initiated
Alternating 2-vector HB-202/HB-201 achieved 80% disease control rate vs historical 35-40% for pembrolizumab.
Hookipa Q1 net loss $18.0M; cash rises to $141.8M on Gilead deal
Cash, equivalents and restricted cash $141.8M (Dec 2021: $66.9M) from Gilead collaboration and follow-on financing.
HOOKIPA reports FY2021 net loss of $75.7M; pro-forma cash $156.9M extends runway to H1 2024
Net loss widened to $75.7M in FY2021 from $44.1M in FY2020; R&D expenses rose to $82.9M.
HOOKIPA Pharma prices $75M public offering of common stock and convertible preferred stock
Issued 21.7M common shares at $2.00/share and 15,800 Series A-1 convertible preferred shares at $2,000 each (each convertible into 1,000 common shares).
Hookipa restates Gilead deal, gets $35M equity; HIV R&D expanded
Hookipa assumes additional HIV development responsibility under restated collaboration agreement.
the Company’s board of directors (the “Board”) appointed Julie O’Neill to serve as non-executive chair of the Board, effective as of the Effective Time.
On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the “Company”) of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time
On August 27, 2024, Timothy Reilly, Ph.D., notified the Company of his resignation as a director of the Company, effective as of the Effective Time.
the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.
On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.
Mr. Kandera also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Financial Officer
On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).
Mr. Aldag also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Executive Officer
changed the title of the Company’s current Chief Development Officer, Dr. Roman Necina, to Chief Operations Officer, effective January 1, 2024.
On October 20, 2023, HOOKIPA Pharma Inc. (the “Company”) announced that Christine Baker, the Company’s Chief Operating Officer, resigned on October 16, 2023 and will be leaving the Company on January 15, 2024, following a garden leave period commencing on November 1, 2023.
On April 7, 2023, Michael A. Kelly, a member of the Board, notified the Company of his resignation from the Board, including the Audit Committee of the Board (the “Audit Committee”), on which he serves as the Chair and a member and the Compensation Committee of the Board on which he serves as a member, effective April 7, 2023.
On March 9, 2023, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Terry Coelho as a director of the Board, effective April 3, 2023.
Max materiality 0.95 · Median 0.70 · Most common event other_material